[Form 4] Pulmonx Corp Insider Trading Activity

Rhea-AI Filing Summary

Pulmonx Corp’s Chief Science & Technology Officer, Radhakrishnan Srikanth, reported routine equity-related transactions in company common stock. On March 2, 2026, he sold a total of 10,483 shares at $1.43 per share solely to cover tax withholding obligations tied to the vesting of previously granted Restricted Stock Units (RSUs) from 2022–2025.

On the same date, he received a grant of 175,000 RSUs, payable solely in Pulmonx common stock, which will vest in equal quarterly installments over a four-year period starting on March 2, 2026. Following these transactions, his directly held common stock position is reported at 345,736 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radhakrishnan Srikanth

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science &Techn. Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		756	D	$1.43	180,463	D
Common Stock	03/02/2026		S(2)		3,068	D	$1.43	177,395	D
Common Stock	03/02/2026		S(3)		2,461	D	$1.43	174,934	D
Common Stock	03/02/2026		S(4)		4,198	D	$1.43	170,736	D
Common Stock	03/02/2026		A		175,000(5)	A	$0	345,736	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

5. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 2, 2026.

	/s/ David Aaron Lehman, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Pulmonx (LUNG) report for Radhakrishnan Srikanth?

Pulmonx reported that Chief Science & Technology Officer Radhakrishnan Srikanth sold 10,483 common shares at $1.43 on March 2, 2026, to cover tax withholding, and received a grant of 175,000 Restricted Stock Units vesting over four years from that date.

Why did Pulmonx’s officer sell 10,483 LUNG shares on March 2, 2026?

The 10,483 Pulmonx shares were sold by the officer solely to cover tax withholding obligations arising from the vesting of RSUs granted in 2022, 2023, 2024, and 2025. These are withholding-related transactions rather than discretionary open-market sales for portfolio or liquidity reasons.

How large is the new RSU grant reported in Pulmonx (LUNG) Form 4?

The Form 4 reports a grant of 175,000 Restricted Stock Units to Radhakrishnan Srikanth. These RSUs are payable solely in Pulmonx common stock and vest in equal quarterly installments over four years, beginning from the grant date of March 2, 2026, subject to their terms.

How many Pulmonx (LUNG) shares does the reporting person hold after these transactions?

After the March 2, 2026 transactions, the reporting person’s directly held Pulmonx common stock position is 345,736 shares. This figure reflects both the tax-withholding share sales and the RSU grant acquisition, as disclosed in the reported post-transaction ownership balances.

What type of acquisition is disclosed in this Pulmonx (LUNG) insider filing?

The filing discloses a grant or award acquisition coded as “A,” representing 175,000 RSUs. These units are payable solely in Pulmonx common stock and will vest in equal quarterly installments over a four-year period starting March 2, 2026, according to the description provided.

Are the Pulmonx (LUNG) insider share sales described as open-market disposals?

While coded as sales, the filing explains these Pulmonx share disposals were executed to satisfy tax withholding obligations upon RSU vesting. Footnotes specify the sold shares relate to RSUs granted between March 1, 2022 and March 3, 2025, rather than discretionary open-market sales.